Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya

AIDS Research and Therapy

Volumn 6, Issue , 2009, Pages

  Steegen, Kim ^a,b,e   Luchters, Stanley ^a,b   Dauwe, Kenny ^a   Reynaerts, Jacqueline ^a   Mandaliya, Kishor ^c   Jaoko, Walter ^d   Plum, Jean ^a   Temmerman, Marleen ^a   Verhofstede, Chris ^a  

^a GHENT UNIVERSITY   (Belgium)

^b International Centre for Reproductive Health Kenya   (Kenya)

^c Department of Obstetrics and Gynaecology   (Kenya)

^d UNIVERSITY OF NAIROBI   (Kenya)

^e Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS RESISTANCE; DRUG EFFECT; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENE SEQUENCE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SHORT COURSE THERAPY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 67650261866     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-6-12     Document Type: Article

References (16)

1. Kenya AIDS Indicator Survey 2007 Nairobi Kenya: National AIDS and STI Control Programme, Ministry of Health Kenya (NASCOP) 2008
2. Guidelines for Antiretroviral Drug Therapy in Kenya Ministry of Health Kenya NASCOP 3 2005
3. WHO Antiretroviral therapy for HIV infection in adults and adolescents: towards universal access. Recommendations for a public health approach Geneva: World Health Organization 2006
4. Steegen K Demecheleer E De Cabooter N Nges D Temmerman M Ndumbe P et al A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance J Virol Methods 2006, 133:137-145. 10.1016/j.jviromet.2005.11.004 16375980
5. Johnson VA Brun-Vezinet F Clotet B Gunthard HF Kuritzkes DR Pillay D et al Update of the Drug Resistance Mutations in HIV-1 Top HIV Med 2008, 16:138-145. 19106428
6. WHO WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV related disease in adults and children Geneva: World Health Organization 2006
7. Coetzee D Hildebrand K Boulle A Maartens G Louis F Labatala V et al Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa AIDS 2004, 18:887-895. 10.1097/ 00002030-200404090-00006 15060436
8. Ferradini L Jeannin A Pinoges L Izopet J Odhiambo D Mankhambo L et al Scaling up of highly active antiretroviral therapy in a rural district of Malawi: An effectiveness assessment Lancet 2006, 367:1335-1342. 10.1016/S0140-6736(06)68580-2 16631912
9. Laurent C Kouanfack C Koulla-Shiro S Njoume M Nkene YM Ciaffi L et al Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine AIDS 2007, 21:768-771. 10.1097/QAD.0b013e328045c4d7 17413701
10. Tassie JM Szumilin E Calmy A Goemaere E Highly active antiretroviral therapy in resource-poor settings: The experience of Medecins Sans Frontieres AIDS 2003, 17:1995-1997. 10.1097/00002030-200309050-00023 12960837
11. Renaud-Thery F Nguimfack BD Vitoria M Lee E Graaff P Samb B Perriens J Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens AIDS 2007, 21(Suppl 4):S89-95. 10.1097/01.aids.0000279711.54922.f0 17620758
12. Tam LW Hogg RS Yip B Montaner JS Harrigan PR Brumme CJ Performance of a World Health Organization first-line regimen (stavudine/lamivudine/ nevirapine) in antiretroviral-naive individuals in a Western setting HIV Med 2007, 8:267-270. 10.1111/j.1468-1293.2007.00463.x 17561871
13. DART Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa AIDS 2006, 20:1391-1399. 16791013
14. Wainberg MA Miller MD Quan Y Salomon H Mulato AS Lamy PD et al In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA Antivir Ther 1999, 4:87-94. 10682153
15. Sungkanuparph S Manosuthi W Kiertiburanakul S Saekang N Pairoj W Chantratita W Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine J Clin Virol 2008, 41:310-313. 10.1016/j.jcv.2007.12.015 18316243
16. Wallis C Bell C Boulme R Sanne I Venter F Papathanasopoulos M Stevens W Emerging ART Drug Resistance in Subtype C: Experience from the 2 Clinics in Johannesburg, South Africa 14th Conference on Retroviruses and Opportunistic Infections (Abstract 661). Los Angeles, US 2007